Table 3.
Cox regression analyses on the multivariate level of rituximab treated patients showing an independent association of baseline characteristics and treatment parameters with the outcome.
| Parameter | PFS, Hazard Ratio (95% CI) | p | OS, Hazard Ratio (95% CI) | p |
|---|---|---|---|---|
| low ALC | 1.960 (1.064–3.610) | 0.031 | 1.416 (0.732–2.738) | 0.302 |
| Age >60 y | 1.646 (0.622–4.355) | 0.316 | 4.244 (0.93–18.136) | 0.051 |
| Stage ≥3 | 0.703 (0.313–1.581) | 0.394 | 0.765 (0.334–1.754) | 0.527 |
| ECOG ≥2 | 1.584 (0.745–3.366) | 0.232 | 1.576 (0.704–3.525) | 0.268 |
| LDH high | 1.825 (0.897–3.712) | 0.097 | 1.767 (0.819–3.809) | 0.147 |
| extranodal sites >1 | 3.224 (1.483–7.010) | 0.003 | 4.149 (1.858–9.266) | 0.001 |
| iv CNS dir | 0.398 (0.191–0.829) | 0.014 | 0.283 (0.123–0.651) | 0.003 |
| Treatment of the contralateral testis | 0.455 (0.250–0.830) | 0.010 | 0.283 (0.123–0.651) | 0.021 |
PFS, progression free survival; OS, overall survival; ALC, absolute lymphocyte count; Age >60 years, patients over 60 years; ECOG, Eastern Cooperative Oncology Group performance score; LDH, lactate dehydrogenase level; IPI, International Prognostic Index; iv CNS dir, intravenous central nervous system directed treatment. Statistically significant p-values are bolded.